Table 4.
Treatment-related adverse events in the three groups.
| Adverse events | T+L+C(n=57) | T+C(n=41) | TACE(n=43) | |||
|---|---|---|---|---|---|---|
| All Grade | Grade3/4 | All Grade | Grade3/4 | All Grade | Grade3/4 | |
| Hypertension | 27(47.4%) | 1(1.8%) | 6(14.6%) | 0 | 0 | 0 |
| fatigue | 29(50.9%) | 0 | 15(36.6%) | 0 | 5(11.6%) | 0 |
| Nausea | 7(12.3%) | 0 | 5(12.2%) | 0 | 5(11.6%) | 0 |
| Abdominal pain | 13(22.8%) | 0 | 8(19.5%) | 0 | 2(4.7%) | 0 |
| Diarrhea | 21(36.8%) | 0 | 10(24.4%) | 0 | 2(4.7%) | 0 |
| appetite decreased | 18(31.6%) | 0 | 12(29.3%) | 0 | 8(18.6%) | 0 |
| Rash | 16(28.1%) | 1(1.8%) | 11(26.8%) | 0 | 0 | 0 |
| Hand-foot syndrome | 21(36.8%) | 0 | 3(7.3%) | 0 | 0 | 0 |
| Mucositis | 9(15.8%) | 0 | 4(9.8%) | 0 | 0 | 0 |
| Hemorrhage | 1(1.8%) | 1(1.8%) | 0 | 0 | 0 | 0 |
| Arthritic pain | 2(3.5%) | 0 | 1(2.4%) | 0 | 0 | 0 |
| Weight loss | 24(42.1%) | 0 | 14(34.1%) | 0 | 8(18.6%) | 0 |
| Leukopenia | 16(28.1%) | 1(1.8%) | 6(14.6%) | 0 | 6(14.0%) | 0 |
| Thrombocytopenia | 24(42.1%) | 5(8.8%) | 11(26.5%) | 2(4.9%) | 17(39.5%) | 0 |
| Elevated TB | 40(70.2%) | 3(5.3%) | 25(61.0%) | 5(12.2%) | 25(58.1%) | 2(4.7%) |
| Elevated ALT | 17(29.8%) | 2(3.5%) | 16(39.0%) | 4(9.8%) | 12(27.9%) | 0 |
| Elevated AST | 23(40.4%) | 7(12.3%) | 24(58.5%) | 4(9.8%) | 20(46.5%) | 2(4.7%) |
| Proteinuria | 3(5.3%) | 1(1.8%) | 0 | 0 | 0 | 0 |
| Hypothyroidism | 5(8.8%) | 0 | 1(2.4%) | 0 | 0 | 0 |
| Immune-related pneumonia | 1(1.8%) | 1(1.8%) | 0 | 0 | 0 | 0 |
Data are presented as n (%). T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase.